Abstract
Combination chemotherapy of Isoniazid, Rifampicin, and Pyrazinamide is the preferred regimen for successful treatment of Tuberculosis (TB). The major complication of otherwise useful Anti-tubercular treatment (ATT) drugs is hepatic damage. There is lack of a definite effective treatment for the same in modern medicine. In view of this, the hepatoprotective activity of an Ayurvedic formulation, Pippali Ghrita (PG), was evaluated in anti-tubercular drug induced hepatotoxicity in Wistar rats. ATT drugs, viz., Isoniazid, Rifampicin, and Pyrazinamide were administered for 30 days to induce hepatotoxicity. Co-administration of PG in study group and Silymarin in standard control group was done for same duration. Hepatotoxicity was assessed on basis of ponderal parameters (body and liver weight) and biochemical parameters, viz., liver function parameters (Aspartate transaminase and Alanine transaminase), and oxidative stress parameters (Malondialdehyde and Superoxide dismutase). Results demonstrated significant increase in body weight and significant reduction in the liver weight, in study group and standard control group as compared to ATT control group. Likewise, significant reduction in liver function parameters and Malondialdehyde levels, with increase in Superoxide dismutase activity were observed, when compared to the ATT control group. The results indicated that co-administration of Pippali Ghrita for 30 days along with ATT prevented anti-tubercular drugs induced hepatotoxicity in Wistar rat model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.